CVS Health (CVS) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $2.12 per share a year ago.
On Wednesday, CVS Health Corp CVS reported fourth-quarter sales of $97.71 billion, beating the consensus of $97.19 billion.
CVS Health reported a smaller-than-expected drop in fourth-quarter profit on Wednesday as the pace of medical cost increases slowed at the healthcare conglomerate and revenues jumped in its pharmacy business, sending its shares up more than 9% in premarket trading.
CVS Health reported fourth-quarter revenue and profit that topped estimates, even as its troubled insurance business saw higher medical costs. The company also issued a full-year 2025 adjusted profit outlook of $5.75 to $6.00 per share, which was in line with Wall Street's expectations.
CVS Health reported $4.6 billion in 2024 profits including $1.6 billion in the fourth quarter as the company worked to overcome rising medical expenses from patients in its health insurance business.
CVS Health Corp CVS will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects 94 cents in EPS and $97.20 billion in revenues as the company reports before market hours.
CVS (CVS 1.23%) is struggling to stay relevant amid rising costs and declining customer visits.
CVS Health investors will closely examine this week turnaround initiatives spearheaded by new CEO David Joyner and their impact on cost pressures in its health insurance business.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
It's more than worthwhile to keep up with what the big money is doing of late. While riding on the coattails of an investing legend may not lead to outperformance in any given year, it can be a subtle sign as to where relative value can be found, regardless of the type of market environment we find ourselves in.
Beyond analysts' top -and-bottom-line estimates for CVS Health (CVS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
On Jan. 30, Walgreens Boots Alliance, a leading pharmacy chain, announced that it was suspending its dividend program, which had been active for over 90 years. This longtime dividend payer is suffering under the weight of financial troubles and had previously resorted to decreasing its payouts.